Jasper Therapeutics, Inc. - 10-Q Filing

Jasper Therapeutics, Inc. reports Q3 2026 financial results including updates on warrant liabilities and equity incentive plan availability.

SEC EDGAR ·

Tickers: $JSPR

Read the full article at SEC EDGAR

More Regulatory news